» Articles » PMID: 27170757

HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites

Overview
Journal J Virol
Date 2016 May 13
PMID 27170757
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The host cell restriction factor CD317/tetherin traps virions at the surface of producer cells to prevent their release. The HIV-1 accessory protein Vpu antagonizes this restriction. Vpu reduces the cell surface density of the restriction factor and targets it for degradation; however, these activities are dispensable for enhancing particle release. Instead, Vpu has been suggested to antagonize CD317/tetherin by preventing recycling of internalized CD317/tetherin to the cell surface, blocking anterograde transport of newly synthesized CD317/tetherin, and/or displacing the restriction factor from virus assembly sites at the plasma membrane. At the molecular level, antagonism relies on the physical interaction of Vpu with CD317/tetherin. Recent findings suggested that phosphorylation of a diserine motif enables Vpu to bind to adaptor protein 1 (AP-1) trafficking complexes via two independent interaction motifs and to couple CD317/tetherin to the endocytic machinery. Here, we used a panel of Vpu proteins with specific mutations in individual interaction motifs to define which interactions are required for antagonism of CD317/tetherin. Impairing recycling or anterograde transport of CD317/tetherin to the plasma membrane was insufficient for antagonism. In contrast, excluding CD317/tetherin from HIV-1 assembly sites depended on Vpu motifs for interaction with AP-1 and CD317/tetherin and correlated with antagonism of the particle release restriction. Consistently, interference with AP-1 function or its expression blocked these Vpu activities. Our results define displacement from HIV-1 assembly sites as active principle of CD317/tetherin antagonism by Vpu and support a role of tripartite complexes between Vpu, AP-1, and CD317/tetherin in this process.

Importance: CD317/tetherin poses an intrinsic barrier to human immunodeficiency virus type 1 (HIV-1) replication in human cells by trapping virus particles at the surface of producer cells and thereby preventing their release. The viral protein Vpu antagonizes this restriction, and molecular interactions with the restriction factor and adaptor protein complex 1 (AP-1) were suggested to mediate this activity. Vpu modulates intracellular trafficking of CD317/tetherin and excludes the restriction factor from HIV-1 assembly sites at the plasma membrane, but the relative contribution of these effects to antagonism remain elusive. Using a panel of Vpu mutants, as well as interference with AP-1 function and expression, we show here that Vpu antagonizes CD317/tetherin by blocking its recruitment to viral assembly sites in an AP-1-dependent manner. These results refine our understanding of the molecular mechanisms of CD317/tetherin antagonism and suggest complexes of Vpu with the restriction factor and AP-1 as targets for potential therapeutic intervention.

Citing Articles

ATG5 selectively engages virus-tethered BST2/tetherin in an LC3C-associated pathway.

Judith D, Versapuech M, Bejjani F, Palaric M, Verlhac P, Kuster A Proc Natl Acad Sci U S A. 2023; 120(20):e2217451120.

PMID: 37155854 PMC: 10193943. DOI: 10.1073/pnas.2217451120.


Host Cell Restriction Factors Blocking Efficient Vector Transduction: Challenges in Lentiviral and Adeno-Associated Vector Based Gene Therapies.

Coroadinha A Cells. 2023; 12(5).

PMID: 36899868 PMC: 10001033. DOI: 10.3390/cells12050732.


Requirement of a functional ion channel for Sindbis virus glycoprotein transport, CPV-II formation, and efficient virus budding.

Elmasri Z, Negi V, Kuhn R, Jose J PLoS Pathog. 2022; 18(10):e1010892.

PMID: 36191050 PMC: 9560593. DOI: 10.1371/journal.ppat.1010892.


Substitutions in Nef That Uncouple Tetherin and SERINC5 Antagonism Impair Simian Immunodeficiency Virus Replication in Primary Rhesus Macaque Lymphocytes.

Janaka S, Snow B, Behrens R, Evans D J Virol. 2022; 96(11):e0017622.

PMID: 35536019 PMC: 9175627. DOI: 10.1128/jvi.00176-22.


An RNA Interference/Adeno-Associated Virus Vector-Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus.

Zhang C, Freistaedter A, Schmelas C, Gunkel M, Dao Thi V, Grimm D Hepatol Commun. 2021; 6(4):878-888.

PMID: 34719133 PMC: 8948557. DOI: 10.1002/hep4.1842.


References
1.
Binette J, Dube M, Mercier J, Halawani D, Latterich M, Cohen E . Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology. 2007; 4:75. PMC: 2170451. DOI: 10.1186/1742-4690-4-75. View

2.
Guo X, Mattera R, Ren X, Chen Y, Retamal C, Gonzalez A . The adaptor protein-1 μ1B subunit expands the repertoire of basolateral sorting signal recognition in epithelial cells. Dev Cell. 2013; 27(3):353-66. PMC: 3992434. DOI: 10.1016/j.devcel.2013.10.006. View

3.
Fritz J, Tibroni N, Keppler O, Fackler O . HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin. Virology. 2012; 424(1):33-44. DOI: 10.1016/j.virol.2011.12.008. View

4.
Goffinet C, Allespach I, Homann S, Tervo H, Habermann A, Rupp D . HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe. 2009; 5(3):285-97. DOI: 10.1016/j.chom.2009.01.009. View

5.
Kueck T, Neil S . A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog. 2012; 8(3):e1002609. PMC: 3315493. DOI: 10.1371/journal.ppat.1002609. View